Pharma BD Deal Intelligence
Merck will pay Moderna $250 million to opt into a co-development agreement for mRNA-4157, an experimental personalized cancer vaccine, the companies announced…
Merck has exercised an option to jointly develop and commercialize Moderna's personalized cancer vaccine mRNA-4157, paying $250 million to enter a 50-50 cost…
Moderna and Merck presented 5-year KEYNOTE-942 data for intismeran autogene (mRNA-4157/V940) + Keytruda in high-risk resected stage III/IV melanoma at the…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Merck and Moderna expanded their existing cancer vaccine collaboration to jointly develop and commercialize mRNA-4157/V940 — now known by its international nonproprietary name intismeran autogene — an individualized neoantigen therapy (INT), in combination with Keytruda (pembrolizumab) for the adjuvant treatment of high-risk resected melanoma and other tumor types. Merck paid $250M upfront to exercise its option for a worldwide 50/50 cost and profit share. The pivotal evidence base is the Phase 2b KEYNOTE-942 trial: initial data showed a 44% reduction in recurrence or death versus Keytruda monotherapy, and five-year follow-up data reported in January 2026 (and presented at the 2026 ASCO Annual Meeting) demonstrated a sustained 49% reduction in the risk of recurrence or death (HR 0.510; 95% CI 0.294-0.887). The pivotal Phase 3 INTerpath-001 melanoma trial is fully enrolled, and Phase 3 NSCLC studies (INTerpath-002 and INTerpath-009) remain in enrollment, with key confirmatory readouts anticipated in 2027.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Moderna, Inc. (this deal) | 2022 | $250M | 86 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
| Merck & Co. Inc. / Prometheus Biosciences Inc. | 2023 | $10.8B | 77 |
← Browse all deals · How we score deals
More: 2022 deals · Merck & Co. Inc. deals · Oncology deals